Natera, Inc. $NTRA is Pura Vida Investments LLC’s 7th Largest Position

Pura Vida Investments LLC lowered its position in shares of Natera, Inc. (NASDAQ:NTRA) by 99.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,500 shares of the medical research company’s stock after selling 243,191 shares during the period. Natera comprises approximately 2.6% of Pura Vida Investments LLC’s holdings, making the stock its 7th largest holding. Pura Vida Investments LLC’s holdings in Natera were worth $402,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in Natera by 11.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 362,767 shares of the medical research company’s stock valued at $58,406,000 after purchasing an additional 36,751 shares during the period. Insigneo Advisory Services LLC purchased a new stake in shares of Natera in the 3rd quarter worth approximately $222,000. Cresset Asset Management LLC bought a new position in shares of Natera during the third quarter valued at approximately $315,000. AustralianSuper Pty Ltd increased its holdings in Natera by 0.7% during the third quarter. AustralianSuper Pty Ltd now owns 195,362 shares of the medical research company’s stock valued at $31,447,000 after buying an additional 1,336 shares during the period. Finally, CI Investments Inc. raised its stake in Natera by 6.6% in the third quarter. CI Investments Inc. now owns 54,146 shares of the medical research company’s stock worth $8,716,000 after buying an additional 3,343 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Citigroup assumed coverage on Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price on the stock. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Barclays lifted their target price on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Piper Sandler raised their price target on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.47.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Natera Price Performance

NASDAQ NTRA opened at $203.03 on Thursday. The company has a market cap of $28.78 billion, a price-to-earnings ratio of -132.70 and a beta of 1.65. The stock’s fifty day moving average price is $224.59 and its 200 day moving average price is $204.76. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter in the previous year, the business earned ($0.41) EPS. Research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 6,939 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the transaction, the chief financial officer directly owned 52,120 shares of the company’s stock, valued at approximately $11,874,499.60. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John Fesko sold 3,594 shares of Natera stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $231.02, for a total transaction of $830,285.88. Following the sale, the insider owned 178,081 shares of the company’s stock, valued at approximately $41,140,272.62. The trade was a 1.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 367,669 shares of company stock worth $85,584,453 in the last ninety days. Corporate insiders own 5.63% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.